Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®
NCT04671810 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44
Last updated 2023-09-13
Summary
This is prospective observational study of long-term pathogenic treatment of Elizaria® in patients with paroxysmal nocturnal hemoglobinuria.
Conditions
Interventions
- BIOLOGICAL
-
Elizaria®
Elizaria® will be prescribed by the Physician according to the actual SMPC.
Sponsors & Collaborators
-
AO GENERIUM
lead INDUSTRY
Principal Investigators
-
Oksana Markova, MD · AO GENERIUM
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-06-13
- Primary Completion
- 2022-12-28
- Completion
- 2023-05-05
Countries
- Russia
Study Locations
More Related Trials
-
Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
NCT00098280 ·Status: COMPLETED ·Phase: PHASE3
-
Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy
NCT04888507 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH
NCT03818607 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Uremic Pruritus With PA101B
NCT02696499 ·Status: COMPLETED ·Phase: PHASE2
-
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
NCT03487913 ·Status: COMPLETED ·Phase: PHASE2
-
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
NCT05744921 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
NCT02536937 ·Status: COMPLETED ·Phase: PHASE1
-
Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT05274633 ·Status: COMPLETED
-
Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria
NCT05741346 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy
NCT05679336 ·Status: RECRUITING ·Phase: NA
-
Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
NCT00130000 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HSK21542 Injection in Subjects Undergoing Hemodialysis
NCT04470154 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
NCT06734234 ·Status: RECRUITING ·Phase: PHASE1
-
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
NCT03056040 ·Status: COMPLETED ·Phase: PHASE3
-
REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.
NCT04162470 ·Status: TERMINATED ·Phase: PHASE3
-
A Retrospective Non-Interventional Study to Evaluate the Impact of Eculizumab in Korean PNH Patients
NCT05337683 ·Status: COMPLETED
-
A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04702568 ·Status: TERMINATED ·Phase: PHASE2
-
Study of GBT021601 in Participants With Renal Impairment
NCT05878704 ·Status: TERMINATED ·Phase: PHASE1
-
Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT02534909 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
NCT04432584 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Renal Impairment Study of PF-06700841
NCT04260464 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus
NCT03218501 ·Status: COMPLETED ·Phase: PHASE2
-
BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy
NCT05116787 ·Status: TERMINATED ·Phase: PHASE2
-
An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
NCT01194973 ·Status: COMPLETED ·Phase: PHASE2
-
The Pharmacokinetics and Pharmacodynamics of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT04079257 ·Status: COMPLETED